
Mitral and tricuspid regurgitation significantly impact outcomes in heart failure, but current trial evidence for transcatheter therapies is limited by patient heterogeneity, evolving disease severity, procedural variability, and small sample sizes. This review explores these limitations and proposes methodological improvements to enhance evidence generation for these promising interventions in atrioventricular valve disease management.
Like
Save
Share